Newly Published: Effectiveness of Covid-19 Vaccines in UK against the B.1.617.2 (Delta) Variant
JL Bernal et al. (2021) report on vaccine efficacy against variants in the United Kingdom, in an original article published (July 21, 2021) in the New England Journal of Medicine. Their study, published as an original report, "Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant," utilized a test-negative case-control design to "estimate the effectiveness of vaccination against symptomatic disease caused by the delta variant or the predominant strain (B.1.1.7, or alpha variant)."
Read more about their methodology, results, and the nuanced discussion in NEJM at Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant | NEJM.
 Bernal et al., 2021, Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant | NEJM, DOI: 10.1056/NEJMoa2108891
This article has been independently reviewed for accuracy by our Scientific Advisory Board. This article has been updated to correct a typographical error.
Part of health disparities news and research reporting by North Carolina Health Equity Project, Inc. The views expressed by the authors of any cited publication(s) or external link(s) do not necessarily reflect the views of North Carolina Health Equity Project, Inc., nor are any affiliations or endorsements implied.
The Mission and Vision of North Carolina Health Equity Project, Inc.
North Carolina Health Equity Project, Inc., NCHEALTHEQ™, develops adaptive, intelligent, next-generation technologies to improve health outcomes for all people, especially those in marginalized communities. We leverage the power of cross-disciplinary innovation and disruptive technologies including AI/ML, “accelerating research and saving lives.” Learn more at https://www.nchealtheq.org/.
Corporate and Governmental Affairs
North Carolina Health Equity Project, Inc.